Powered by

Trump's drug price crack down could squeeze Regeneron and Eylea profits

Nov 06, 2018 - Albany Business Review

Regeneron Pharmaceutical's biggest-selling drug is among 27 medications facing sharp price cuts under the Trump administration's quest to drive down Medicare spending.

"Something has to change in how Medicare pays for physician-administered drugs," said U.S. Health and Human Services Secretary Alex Azar.

The United States government, through the Medicare Part B program, pays 80 percent more than several other countries pay for the same drugs, according to an analysis by Health and Hu...